Cerevel Therapeutics Holdings, Inc.

NasdaqCM:CERE Voorraadrapport

Marktkapitalisatie: US$8.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Cerevel Therapeutics Holdings Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Cerevel Therapeutics Holdings has a total shareholder equity of $564.5M and total debt of $451.9M, which brings its debt-to-equity ratio to 80.1%. Its total assets and total liabilities are $1.1B and $562.9M respectively.

Belangrijke informatie

80.1%

Verhouding schuld/eigen vermogen

US$451.92m

Schuld

Rente dekkingsration/a
ContantUS$846.29m
AandelenUS$564.46m
Totaal verplichtingenUS$562.89m
Totaal activaUS$1.13b

Recente financiële gezondheidsupdates

Recent updates

Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Apr 30
Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Jan 02
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Cerevel overweight at Wells Fargo due to candidates with blockbuster potential

Sep 26

Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering

Aug 12

Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13

Aug 01

Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded

Jul 08

Cerevel Therapeutics: Pfizer's Neurology Spin-Off

Jul 14

We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Jun 09
We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Jan 29
Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Cerevel Therapeutics (CERE) Investor Presentation - Slideshow

Nov 18

Cerevel Therapeutics reports Q3 results

Nov 16

Analyse van de financiële positie

Kortlopende schulden: CERE's short term assets ($859.6M) exceed its short term liabilities ($84.1M).

Langlopende schulden: CERE's short term assets ($859.6M) exceed its long term liabilities ($478.8M).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: CERE has more cash than its total debt.

Schuld verminderen: CERE's debt to equity ratio has increased from 7.4% to 80.1% over the past 5 years.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: CERE has sufficient cash runway for more than a year based on its current free cash flow.

Voorspelling contante baan: CERE has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 31.2% each year.


Ontdek gezonde bedrijven